title: Fibrinolytic therapy for thrombosis in cardiac valvular prosthesis short and long term results.
abstract: OBJECTIVE
  To assess the short- and long-term results of the use of streptokinase (SK) for the treatment of thromboses in cardiac valvular prostheses.
  
  
  METHODS
  Seventeen patients with cardiac prosthetic thrombosis diagnosed by clinical, echocardiographic, and radioscopic findings underwent fibrinolytic treatment with a streptokinase bolus of 250,000 U followed by 100.000 U/hour. Short- and long-term results were assessed by radioscopy and echocardiography.
  
  
  RESULTS
  Of the 17 patients, 12 had mechanical double-disk prostheses (4 aortic, 6 mitral, 2 tricuspid), 4 had single-disk prostheses (2 aortic, 1 mitral, and 1 tricuspid), and 1 had a tricuspid bioprosthesis. The success rate was 64.8%, the partial success rate was 17.6%, and the nonsuccess rate was 17.6%. All patients with a double-disk prosthesis responded, completely or partially, to the treatment. None of the patients with a single-disk prosthesis had complete resolution of the thrombosis. The time of streptokinase infusion ranged from 6 to 80 hours (mean of 56 h). The mortality rate due to the use of streptokinase was 5.8% and was secondary to cerebral bleeding. During streptokinase infusion, 3 (17.6%) embolic episodes occurred as follows: 1 cerebral, 1 peripheral, and 1 coronary. The rethrombosis index was 33% in a mean follow-up of 42 months.
  
  
  CONCLUSIONS
  The use of fibrinolytic agents was effective and relatively safe in patients with primary thrombosis of a double-disk prosthesis. A fatal hemorrhagic complication occurred in 1 (5.8%) patient, and embolic complications occurred in 3 (17.6%) patients. In a mean 42-month follow-up, 67% of the patients were free from rethrombosis.
authors.affiliation: Instituto Dante Pazzanese de Cardiologia, São Paulo, SP, Brazil. rafframos@uol.com.br
authors.forename: Auristela I O
authors.initials: AI
authors.lastname: Ramos
authors.forename: Rui F
authors.initials: RF
authors.lastname: Ramos
authors.forename: Dorival J D
authors.initials: DJ
authors.lastname: Togna
authors.forename: Antoninho S
authors.initials: AS
authors.lastname: Arnoni
authors.forename: Rodolfo
authors.initials: R
authors.lastname: Staico
authors.forename: Mercedes M
authors.initials: MM
authors.lastname: Galo
authors.forename: Zilda M
authors.initials: ZM
authors.lastname: Meneghelo
mesh_terms: D000293:Adolescent; D000328:Adult; D002648:Child; D002933:Cineradiography; D015150:Echocardiography, Doppler; D017548:Echocardiography, Transesophageal; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D006350:Heart Valve Prosthesis / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D013300:Streptokinase / Q000627:therapeutic use*; D015912:Thrombolytic Therapy / Q000379:methods*; D013927:Thrombosis / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D016896:Treatment Outcome
chemical_list: D005343:Fibrinolytic Agents; D013300:Streptokinase